" class="no-js "lang="en-US"> Antoine Prestat - Medtech Alert
Wednesday, March 22, 2023

Breaking News

Axel Hoos, MD, PhD, Joins NextPoint Therapeutics Board of Directors Coya Therapeutics Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS) BeiGene Enters New Phase to Expand US Manufacturing and R&D Footprint in New Jersey Mindset Health Raises $12M to Expand Digital Hypnotherapy Apps & Scale Distribution GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey” Dupixent® (dupilumab) Approved by European Commission as First and Only Targeted Medicine for Children as Young as Six Months Old with Severe Atopic Dermatitis Gamida Cell Announces Changes to Board of Directors Newron Reports Topline Results From All Patients in Study Evaluating Evenamide as Add-on Therapy for Treatment-Resistant Schizophrenia Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief Medical Officer TFS HealthScience Expands Operations into Israel, With Focus on Continuous, Rapid International Expansion
Antoine Prestat

Antoine Prestat

About Antoine Prestat

Entrepreneur in biotechnology. Licensing-in & -out. Marketing and Business Development of innovative technologies in Life-Sciences. Project & Team Management.

Related Story

Clinical Trials

 PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase I Clinical Trial of PEP-010 for the Treatment of Advanced Solid Tumors | Pharmtech Focus

PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase I Clinical Trial of PEP-010 for the Treatment of Advanced Solid Tumors

October 5 2021

PEP-Therapy, a clinical-stage biotechnology company developing cell penetrating peptides as targeted therapies in oncology, and […]

Diseases

 PEP-Therapy Extends Series-A Financing

PEP-Therapy Extends Series-A Financing, Raising a Total of €5.4 Million to Progress the Clinical Development of its Lead Candidate PEP-010

July 19 2021

PEP-Therapy, a biotechnology company developing cell penetrating peptides as targeted therapies for the treatment of […]